Ticker
AFMD

Price
2.04
Stock movement down
-0.05 (-2.39%)
Company name
Affimed NV
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Markedsverdi
304.61M
Ent verdi
210.59M
Pris/omsetning
10.61
Pris/bok
-
Utbytte avkastning
-
Utbytte vekst
-
Vekst år
-
FCF-utbetaling
-
Etterfølgende P/E
-
Fremtidig P/E
-
PEG
-
EPS-vekst
-
1 års avkastning
-70.73%
3 års avkastning
-6.05%
5 års avkastning
-0.58%
10 års avkastning
-
Sist oppdatert: 2022-11-29

UTBYTTE

AFMD betaler ikke utbytte

VERDSETTELSE

Verdsettelsesforhold

Loading...
Verdsettelsesforhold-data
Etterfølgende P/E-
Pris til OCF-
Pris til FCF-
Pris til EBITDA-
EV i forhold til EBITDA-

Verdsettelse (Salg/Bokført verdi)

Loading...
Verdsettelse (Salg/Bokført verdi) data
Pris til omsetning10.61
Pris til bok-
EV i forhold til salg7.34

ØKONOMI

Per aksje

Loading...
Per aksje-data
Gjeldende aksje antall149.32M
EPS (TTM)-
FCF per aksje (TTM)-

Resultatregnskap

Loading...
Resultatregnskap-data
Inntekter (TTM)28.71M
Bruttofortjeneste (TTM)0.00
Driftsinntekter (TTM)-59.95M
Netto inntekt (TTM)-58.94M
EPS (TTM)-
EPS (1 år fremover)-0.76

Marginer

Loading...
Marginer-data
Bruttomargin (TTM)-
Driftsmargin (TTM)-208.82%
Fortjenestemargin (TTM)-205.30%

Balanse

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Balanse-data
Kontanter169.85M
Netto fordringer4.55M
Samlede omløpsmidler180.93M
Goodwill0.00
Immaterielle eiendeler0.00
Eiendom, anlegg og utstyr0.00
Sum eiendeler193.25M
Leverandørgjeld13.54M
Kortsiktig/nåværende langsiktig gjeld18.63M
Sum kortsiktig gjeld57.80M
Sum gjeld75.83M
Aksjonærenes egenkapital0.00
Netto varige driftsmidler115.84M

Kontantstrøm

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Kontantstrøm-data
Kontantstrøm fra drift (TTM)-98.98M
Kapitalutgifter (TTM)2.99M
Fri kontantstrøm (TTM)-101.97M
Utbetalt utbytte (TTM)0.00

Finansielle inntekter

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Finansielle inntekter-data
Egenkapitalavkastning-
Avkastning på eiendeler-
Avkastning på investert kapital-
Kontantavkastning på investert kapital-

AKSJEINFORMASJON

Aksjediagram

Loading...
Aksjekurs-data
Åpning2.11
Daglig høy2.15
Daglig lav2.01
Daglig volum1.89M
Tidenes høyeste21.93
1 år analytikerestimat11.92
Beta2.43
EPS (TTM)-
Utbytte per aksje-
Ex-div dato-
Neste dato for resultatpresentasjon-

Nedsidepotensial

Loading...
Nedsidepotensial-data
AFMDS&P500
Nåværende prisfall fra toppnotering-90.70%-17.12%
Høyeste prisfall-94.41%-56.47%
Dato for høyeste fall13 Dec 20179 Mar 2009
Gj.snittlig fall fra topp-75.55%-11.46%
Gj.snittlig tid til ny topp83 days13 days
Maks tid til ny topp1856 days1805 days
SELSKAPSOPPLYSNINGER
AFMD (Affimed NV) company logo
Markedsverdi
304.61M
Markedsverdi kategori
Small-cap
Beskrivelse
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia; and AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. Affimed N.V. has collaboration agreements with The University of Texas MD Anderson Cancer Center; Genentech, Inc.; and Roivant Sciences Ltd., as well as research funding agreement with The Leukemia & Lymphoma Society. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.
Ansatte
197
Investorrelasjoner
-
SEC-innsendelser
Adm. direktør
Adolf Hoess
Land
USA
By
Heidelberg
Aksjetype
Common stock
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRESENTASJONER
ArrangementerPresentasjoner
Loading...
FORSTÅ VIRKSOMHETEN
Loading...
NYHETER OM SELSKAPET
Alle nyheterPressemeldinger
Shares of German immuno-oncology company Affimed Therapeutics (NASDAQ: AFMD) were down a little more than 15% on Thursday afternoon. There was no big news from the biotech company, but clinical-stage...
17. november 2022
Affimed ( NASDAQ:AFMD ) Third Quarter 2022 Results Key Financial Results Revenue: €15.0m (up 69% from 3Q 2021). Net...
17. november 2022
Affimed N.V. (AFMD) delivered earnings and revenue surprises of 42.11% and 96.03%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
15. november 2022
AFM13: Secured access to commercially viable natural killer (NK) cell product to accelerate clinical development of AFM13 and address the high unmet need of CD30-positive lymphoma patients through a c...
15. november 2022
Comprehensive correlative science findings from patients treated with AFM24 monotherapy indicate an activation of NK cells and their migration to the tumorInitial signs of clinical activity and a well...
7. november 2022
HEIDELBERG, Germany, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innat...
4. november 2022
Companies to combine their clinical programs (AFM13, AB-101) to address high unmet need of CD30-positive lymphoma patientsAffimed’s AFM13 in combination with cord blood-derived NK cells demonstrated e...
3. november 2022
In 24 patients with CD30-positive lymphoma treated at the highest dose level, the combination treatment of AFM13 with allogeneic NK cells continues to achieve a 100% overall response rate and an impro...
3. november 2022
Affimed N.V. (AFMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2. november 2022
HEIDELBERG, Germany, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innat...
1. november 2022
Neste side